Tenaya Therapeutics, Inc.
TNYANasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$93.3M | −$115.9M | −$131.2M | −$125.6M | −$72.8M | −$38.9M |
| Net income | −$90.6M | −$111.1M | −$124.1M | −$123.7M | −$72.7M | −$38.4M |
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M | $314.2M | $148.2M |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M | $35.7M | $8.7M |
| Equity | $123.3M | $92.9M | $139.4M | $243.4M | $278.5M | −$81.3M |
| EPS (diluted) | $-0.59 | $-1.31 | $-1.68 | $-2.76 | $-4.10 | — |
| Shares out. | 87.6M | 78.5M | 66.9M | 41.3M | 41.3M | 1.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −73.5%
- Return on assets
- −61.7%
- Return on capital (ROCE)
- −71.0%
- Liabilities / assets
- 16.1%
- Debt / equity
- 0.19×
- Book value / share
- $1.41
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -8.20distress
- Accruals / assets
- −15.2%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-05-01Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
- Phase 1/2Recruitingreadout ~2027-08Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ali FarazOfficer — Chief Executive Officer | May 18, 2026 | Sell | 3,390 | $0.79 |
| Tingley WhittemoreOfficer — Chief Medical Officer | May 18, 2026 | Sell | 3,121 | $0.79 |
| Higa TomohiroOfficer — SVP, Finance | May 18, 2026 | Sell | 1,485 | $0.79 |
| Column Group Iii Gp, Lp10% owner | Feb 24, 2026 | Sell | 309,228 | $0.62 |
| Column Group Iii Gp, Lp10% owner | Feb 20, 2026 | Sell | 245,965 | $0.61 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 28.8M | 4.4 | +3.0% |
| Apr 30, 2026 | 27.9M | 8.6 | +7.0% |
| Apr 15, 2026 | 26.1M | 9.1 | +3.5% |
| Mar 31, 2026 | 25.2M | 8.4 | -0.3% |
| Mar 13, 2026 | 25.3M | 2.9 | +7.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 29, 2026
- Results of operationsMay 6, 2026
- Results of operationsMar 11, 2026
- Entered a material agreementMar 5, 2026
- Delisting / listing-standard notice · Director / officer changeJan 30, 2026
- Director / officer changeJan 2, 2026
- Entered a material agreement · Regulation FD disclosureDec 12, 2025
- Regulation FD disclosure · Other material eventDec 11, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.